Paper31190820
Hypoxia-active nanoparticles used in tumor theranostic.
Wang Y and 4 others. Int J Nanomedicine, 2019. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. Hypoxia-active nanoparticles used in tumor theranostic. Papers, record 31190820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31190820
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nanoparticles | Major topic |
| Theranostic Nanomedicine | Major topic |
| Tumor Hypoxia | Major topic |
| Diagnostic Imaging | |
| Humans | |
| Hypoxia-Inducible Factor 1, alpha Subunit | |
| Neoplasms |
Source PubMed
References139
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10476219 | PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. | Gene Ther | 1999 | https://conductscience.org/library/papers/10476219 | PubMed |
| 2 | 11283581 | A clearer vision for in vivo imaging. | Nat Biotechnol | 2001 | https://conductscience.org/library/papers/11283581 | PubMed |
| 3 | 11341468 | 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. | Oncol Res | 2000 | https://conductscience.org/library/papers/11341468 | PubMed |
| 4 | 11375747 | Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. | Curr Med Chem | 2001 | https://conductscience.org/library/papers/11375747 | PubMed |
| 5 | 11472243 | Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. | Curr Med Chem | 2001 | https://conductscience.org/library/papers/11472243 | PubMed |
| 6 | 11599887 | Effect of a hypoxic radiosensitizer, AK 2123 (Sanazole), on yeast Saccharomyces cerevisiae. | J Radiat Res | 2001 | https://conductscience.org/library/papers/11599887 | PubMed |
| 7 | 11705453 | Metabolism of tirapazamine by multiple reductases in the nucleus. | Biochem Pharmacol | 2001 | https://conductscience.org/library/papers/11705453 | PubMed |
| 8 | 11902584 | Hypoxia--a key regulatory factor in tumour growth. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/11902584 | PubMed |
| 9 | 12234992 | Tirapazamine: a hypoxia-activated topoisomerase II poison. | Cancer Res | 2002 | https://conductscience.org/library/papers/12234992 | PubMed |
| 10 | 12399448 | Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice. | Physiol Genomics | 2002 | https://conductscience.org/library/papers/12399448 | PubMed |
| 11 | 12489027 | Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. | Cancer Gene Ther | 2003 | https://conductscience.org/library/papers/12489027 | PubMed |
| 12 | 12859987 | Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress. | Arch Biochem Biophys | 2003 | https://conductscience.org/library/papers/12859987 | PubMed |
| 13 | 13130303 | Targeting HIF-1 for cancer therapy. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/13130303 | PubMed |
| 14 | 14069241 | MITOMYCIN C: CHEMICAL AND BIOLOGICAL STUDIES ON ALKYLATION. | Science | 1963 | https://conductscience.org/library/papers/14069241 | PubMed |
| 15 | 14162693 | MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. | Science | 1964 | https://conductscience.org/library/papers/14162693 | PubMed |
| 16 | 14654556 | NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14654556 | PubMed |
| 17 | 15642166 | The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone. | Breast Cancer Res | 2005 | https://conductscience.org/library/papers/15642166 | PubMed |
| 18 | 15819391 | Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines. | Arzneimittelforschung | 2005 | https://conductscience.org/library/papers/15819391 | PubMed |
| 19 | 16125243 | Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. | Neurotoxicology | 2006 | https://conductscience.org/library/papers/16125243 | PubMed |
| 20 | 16268634 | Synthesis and luminescence of soluble meso-unsubstituted tetrabenzo- and tetranaphtho[2,3]porphyrins. | J Org Chem | 2005 | https://conductscience.org/library/papers/16268634 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42226962 | Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42226962 | PubMed |
| 41497307 | Hypoxia-responsive Exatecan prodrug liposomes co-delivered with IR808 for synergistic chemo-photodynamic therapy of breast cancer. | Int J Pharm X | 2025 | https://conductscience.org/library/papers/41497307 | PubMed |
| 40297580 | Immunocytes in the tumor microenvironment: recent updates and interconnections. | Front Immunol | 2025 | https://conductscience.org/library/papers/40297580 | PubMed |
| 39816693 | Hypoxia-responsive nanoparticles for fluorescence diagnosis and therapy of cancer. | Theranostics | 2025 | https://conductscience.org/library/papers/39816693 | PubMed |
| 39652186 | Cellular and molecular aspects of drug resistance in cancers. | Daru | 2024 | https://conductscience.org/library/papers/39652186 | PubMed |
| 39459028 | Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39459028 | PubMed |
| 39281920 | Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies. | ACS Omega | 2024 | https://conductscience.org/library/papers/39281920 | PubMed |
| 39273657 | A Hypoxia-Decidual Macrophage Regulatory Axis in Normal Pregnancy and Spontaneous Miscarriage. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273657 | PubMed |
| 39179514 | Novel Prodrug Strategies for the Treatment of Tuberculosis. | Chem Asian J | 2024 | https://conductscience.org/library/papers/39179514 | PubMed |
| 38675218 | Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38675218 | PubMed |
| 38675124 | Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38675124 | PubMed |
| 38398021 | Tumor Microenvironment-Responsive Drug Delivery Based on Polymeric Micelles for Precision Cancer Therapy: Strategies and Prospects. | Biomedicines | 2024 | https://conductscience.org/library/papers/38398021 | PubMed |
| 37915127 | Stimuli-Responsive Nanotechnology for RNA Delivery. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37915127 | PubMed |
| 37841921 | Photodynamic therapy and associated targeting methods for treatment of brain cancer. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37841921 | PubMed |
| 37443821 | Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy. | Cells | 2023 | https://conductscience.org/library/papers/37443821 | PubMed |
| 37056346 | Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point? | Front Oncol | 2023 | https://conductscience.org/library/papers/37056346 | PubMed |
| 36980778 | The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980778 | PubMed |
| 36365094 | Mitophagy Induced by Metal Nanoparticles for Cancer Treatment. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36365094 | PubMed |
| 36295845 | Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia. | Metabolites | 2022 | https://conductscience.org/library/papers/36295845 | PubMed |
| 36096856 | Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36096856 | PubMed |
Genes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31190820
GET https://conductscience.org/api/papers/v1/31190820/references?page=2